金石亚药: 关于与关联方签订产品推广委托协议暨关联交易的公告

Group 1 - The company approved a related party transaction involving a product promotion agreement between its wholly-owned subsidiary Zhejiang Kuaike Pharmaceutical Co., Ltd. and its associate Hangzhou Lingye Pharmaceutical Co., Ltd. The transaction amount is expected to be no more than RMB 15 million (including tax) [1][2][6] - The promotion period for the product, dexamethasone ointment, is from the effective date of the agreement until December 31, 2026 [1][4] - The company holds a 32.4304% stake in Lingye Pharmaceutical, which is considered a related party due to the involvement of the company's chairman and president in its management [2][4] Group 2 - The product involved in the agreement is dexamethasone ointment, which is a corticosteroid used for treating various skin conditions. It has been clinically validated for efficacy and safety [4][6] - The transaction pricing is based on market rates and is deemed fair and reasonable, ensuring no harm to the interests of the company's shareholders, particularly minority shareholders [5][7] - The independent directors of the company have reviewed and approved the transaction, confirming compliance with relevant laws and regulations, and asserting that it will not adversely affect the company's financial status or operational results [7]